Coherus Oncology Finalizes $50.05M Public Offering, Securing Operating Capital

summarizeSummary

Coherus Oncology, Inc. finalized an underwritten public offering of 28.6 million shares at $1.75 per share, raising approximately $47.05 million in net proceeds to fund operations and product development through 2026.

check_boxKey Events

• Offering Finalized

  Coherus Oncology finalized an underwritten public offering of 28,600,000 shares of common stock at $1.75 per share, generating gross proceeds of $50,050,000.

• Significant Capital Raise

  The company expects to receive approximately $47.05 million in net proceeds, or up to $53.6 million if the underwriters fully exercise their over-allotment option.

• Substantial Dilution

  The offering will increase the number of outstanding shares by approximately 22.78%, leading to significant dilution for current shareholders.

• Pricing Dynamics

  The offering price of $1.75 per share represents a discount to the last reported sale price of $2.04 on February 11, 2026, but is at a premium to the current stock price of $1.63.

auto_awesomeAnalysis

Coherus Oncology, Inc. has finalized the terms of its underwritten public offering, initially disclosed in a preliminary prospectus supplement on February 12, 2026. The company will issue 28.6 million shares of common stock at a public offering price of $1.75 per share, raising approximately $47.05 million in net proceeds. This offering represents a substantial capital raise, equivalent to over 25% of the company's current market capitalization, and will result in significant dilution for existing shareholders. The offering price of $1.75 per share is at a discount to the last reported sale price of $2.04 on February 11, 2026, but notably, it is at a premium to the current stock price of $1.63. The proceeds are earmarked for the commercialization of LOQTORZI, clinical development of product candidates, and general corporate purposes, which the company states will fund operations through the end of 2026. This capital infusion is critical for a life sciences company like Coherus Oncology to maintain its operational runway and advance its pipeline.